Paradigm Pharma (cambodia) Co. Ltd

[Lcs Basinger]

Underthe Law on Patents in force in Cambodia, pharmaceutical products now stand excluded from patent protection [Article 4(iv) and Article 136 of the amended Law on Patents (Royal Kram N NS/RKM/1117/016)].

Under the Law on Management of Pharmaceutical promulgated by Kram No. ChS/RKM/0696/02 dated on June 17, 1996 and amendment adopted by the National Assembly of the Kingdom of Cambodia on November 8, 2007, a pharmaceutical is one or many kinds of substances which are primarily from chemicals, bio-products, microbes, plants combined in order to use in the prevention or treatment of human or animal diseases, or to use in the medical or pharmaceutical research or diagnosis, or change or support the functioning of the organs.

Furthermore, Cambodia currently benefits from the World Trade Organization waiver allowing Least Developed Countries (LDCs) to avoid granting and enforcing IP rights on pharmaceutical products until 2033.

The establishment of the World Trade Organization (WTO) has led to a paradigm shift in world trade. The agreement on Trade-Related (Aspects of) Intellectual Property Rights (TRIPS) was negotiated during the round trade negotiations of the General Agreement on Tariffs and Trade (GATT) in Uruguay and the pharmaceutical industry was one of the primary reasons for incorporating intellectual property issues into the framework of GATT. India became a signatory to the GATT on April 15, 1994, which mandated to comply with the requirements of GATT, including the agreement on TRIPS.

Hence, India is required to meet the minimum standards under the TRIPS Agreement in relation to patents and the pharmaceutical industry. Patents are to be granted for a minimum term of 20 years to any invention of a pharmaceutical product or process that fulfils established criteria.

The Phase 3 TIMES program was a joint development effort between Poxel and Sumitomo Dainippon Pharma. The companies entered into a strategic partnership in October 2017 for the development and commercialization of TWYMEEG in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries4.The approval triggers a JPY1.75 billion (approximately EUR13.3 million, USD15.9 million)5 milestone payment to Poxel. Furthermore, after product launch, Poxel is entitled to receive escalating double-digit royalties on net sales and sales-based payments of up to JPY26.5 billion (approximately EUR200 million, USD230 million)6 in accordance with sales goals.

Imeglimin is the first agent in a new chemical class of tetrahydrotriazine-containing molecules. It is thought that TWYMEEG shows a glucose lowering effect by both a pancreatic action that promotes glucose concentration-dependent insulin secretion and an extra-pancreatic action that improves glucose metabolism in the liver and skeletal muscle (suppression of gluconeogenesis and improvement of glucose uptake) through an action on mitochondria. This mechanism of action (MOA) has the potential to prevent endothelial and diastolic dysfunction, which could provide protective effects on micro- and macrovascular defects induced by diabetes. It also has the potential for protective effects on beta-cell survival and function. This unique MOA offers the potential opportunity for Imeglimin to be a candidate for the treatment of type 2 diabetes in almost all stages of the current anti-diabetic treatment paradigm, including monotherapy or as an add-on to other glucose lowering therapies.

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business.

Sumitomo Dainippon Pharma defines its corporate mission as "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide". By channeling our efforts into the research and development of new drugs, we aim to realize our mission and provide innovative and effective pharmaceutical solutions not only to people in Japan but also around the world. Sumitomo Dainippon Pharma's goal is to create innovative pharmaceutical products in the focus research areas of psychiatry and neurology, oncology, and regenerative medicine/cell therapy. For more detail, please visit our website. (URL: -pharma.com)

Jane Buckner, MD, is the president of the Benaroya Research Institute at Virginia Mason (BRI), affiliate professor of immunology at the University of Washington, and affiliate professor of Medicine, Division...

Carla Greenbaum, MD, is director of the Diabetes Program and Center for Interventional Immunology at BRI and the director of the NIH-sponsored TrialNet Clinical Network Hub. After medical school at...

The development of teplizumab and the results indicating that it can delay T1D diagnosis are founded on data from several long-running international studies demonstrating that is possible to identify individuals destined to develop T1D based on the presence of multiple T1D-associated autoantibodies. Strikingly, essentially all of these individuals will eventually develop T1D, but teplizumab delayed disease onset by a median of two years, and longer for some individuals.

To put those numbers in context, we routinely screen for high blood pressure. Left untreated, about 2 to 3 percent of people with high blood pressure will develop a stroke or heart attack within five years. This risk is considered a big enough problem that instead of merely telling patients they are at risk of future stroke or heart disease, we give high blood pressure a name: hypertension. We recognize the importance of screening to find people with hypertension because we know that early identification matters to those people who will experience the worst outcomes. This works because we have therapies that can prevent or reduce the risk of stroke and heart attacks. In the case of T1D, as essentially all of those at high risk will eventually develop T1D, everyone treated has the potential to benefit from therapy.

Furthermore, with the FDA approval of teplizumab, there is now precedent for therapies to prevent other autoimmune diseases as well. The milestone demonstrates to the NIH that decades of funding natural history studies in T1D were worthwhile, and to the biotech and pharmaceutical industries that there is a pathway for FDA approval for therapies that prevent these diseases.

Through work at our institution, the Benaroya Research Institute, and elsewhere, we know that T1D is not the only disease with an asymptomatic early stage. We are developing the tools to predict who is going to develop rheumatoid arthritis (RA), and early detection research for multiple sclerosis is accelerating. Critically, echoing T1D, prevention in RA is also moving ahead, including trials testing whether a therapy called abatacept can delay development of the disease in those who are flagged as being at risk primarily based on the presence of autoantibodies.

While the approval of teplizumab is transformative, how rapidly it and similar therapies will change clinical practice remains an open question. Here, the complicated dynamics of the US healthcare system play a role. Clinical practice standards will need to change such that screening for, and early detection of, autoimmune diseases becomes routine. Insurers will need to pay for screening, monitoring, and the new preventive treatments. Clinicians will need to be educated about this new paradigm, and patients will need to understand their new diagnoses and their treatment options. Sadly, paradigm shifts in clinical practice are slow, and clinicians are hard pressed for the time to discuss screening and prevention in a standard 15-minute appointment. Advancements in preventive care may end up being driven by individuals living with autoimmune diseases since personal experience with the disease can lead to advocacy for screening and early detection.

A first glance at the scant, formulaic interviews available on the internet with Pcoul backs up this version of events. His Wikipedia entry consists of just three short paragraphs, sourced from a single reference linking to a 2017 WaybackMachine archive of the website of DNDi, the organization he founded and has led for the last 19 years.

He has made a habit of understating his accomplishments, but behind the scenes, Pcoul has been a silent force behind a paradigm shift in global health and humanitarianism over the past 30 years that continues to unfold to this day.

Pcoul had initially planned to join MSF for just six months, but his encounters with sleeping sickness patients in Uganda and the Democratic Republic of Congo (DRC) in the 1980s, then still territories in Zaire, quickly led to a deep sensibility to the inequalities affecting those he was sent to help. A few months in, he decided to stay and would remain at MSF for the next two decades.

Even 30 years later, the memories of these formative experiences that made clear to him and his colleagues the need for urgent action to address the crisis in neglected diseases remain vivid and painful.

By the time Fexinidazole was approved, DNDi had developed eight novel treatment combinations for neglected diseases. These included ASAQ, a revolutionary oral malaria treatment passed on to the Medicines for Malaria Venture in 2015 that has been distributed to nearly 600 million patients.

With most of the disease burden falling on developing regions, where few could afford high prices for treatments, and new blockbuster drugs generating ever-increasing financial gains for shareholders in rich countries, pharmaceutical giants showed little interest in developing drugs for neglected diseases. The bottom line rewards could not be justified.

3a8082e126